Antithymocyteglobulin as prophylaxis of graft failure and graft-versus-host disease in recipients of partially T-cell-Depleted grafts from matched unrelated donors: A dose-finding study

Experimental Hematology

Volumn 31, Issue 11, 2003, Pages 1026-1030

  Meijer, Ellen ^a   Cornelissen, Jan J ^b   Löwenberg, Bob ^b   Verdonck, Leo F ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; THYMOCYTE ANTIBODY;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGED; APLASTIC ANEMIA; ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; GRANULOCYTE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; PROPHYLAXIS; T LYMPHOCYTE; THROMBOCYTE;

EID: 0142165064     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(03)00204-2     Document Type: Article

References (21)

1. Kernan N.A., Bartsch G., Ash R.C., et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med. 328:1993;593-602.
2. McGlave P.B., Shu X.O., Wen W., et al. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the national marrow donor program. Blood. 95:2000;2219-2225.
3. Champlin R.E., Passweg J.R., Zhang M.J., et al. T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood. 95:2000;3996-4003.
4. Ho V.T., Soiffer R.J. The history and future of T-cell depletion as graft-vs-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood. 98:2001;3192-3204.
5. Voogt P.J., Fibbe W.E., Marijt W.A., et al. Rejection of bone-marrow graft by recipient-derived cytotoxic T lymphocytes against minor histocompatibility antigens. Lancet. 335:1990;131-134.
6. Fleischhauer K., Kernan N.A., O'Reilly R.J., Dupont B., Yang S.Y. Bone marrow-allograft rejection by T lymphocytes recognizing a single amino acid difference in HLA-B44. N Engl J Med. 323:1990;1818-1822.
7. Bacigalupo A., Oneto R., Lamparelli T., et al. Pre-emptive therapy of acute graft-vs-host disease: a pilot study with antithymocyte globulin (ATG). Bone Marrow Transplant. 28:2001;1093-1096.
8. Bacigalupo A., Lamparelli T., Bruzzi P., et al. Antithymocyte globulin for graft-vs-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood. 98:2001;2942-2947.
9. Duval M., Pedron B., Rohrlich P., et al. Immune reconstitution after haematopoietic transplantation with two different doses of pre-graft antithymocyte globulin. Bone Marrow Transplant. 30:2002;421-426.
10. Anderson R.A., Booth K.R., Saunders C., Coppes M.J., Russell J.A. Low dose antithymocyteglobulin incorporated into GVHD prophylaxis improves GVHD but not other outcomes after pediatric unrelated donor bone marrow transplantation. [abstract] Blood. 98:2001;S335a. Abstract 5306.
11. Russell J.A., Tran H.T., Quinlan D., et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant. 8:2002;468-476.
12. Duggan P., Booth K., Chaudhry A., et al. Unrelated donor BMT recipients given pretransplant low-dose antithymocyte globulin have outcomes equivalent to matched sibling BMT: a matched pair analysis. Bone Marrow Transplant. 30:2002;681-686.
13. Byrne J.L., Stainer C., Cull G., et al. The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-vs-host disease and outcome following unrelated donor bone marrow transplantation for leukemia. Bone Marrow Transplant. 25:2000;411-417.
14. Holler E., Ledderose G., Knabe H., Gunther C., Wilmanns W., Kolb H.J. ATG serotherapy during pretransplant conditioning in unrelated donor BMT: dose dependent modulation of GVHD. [abstract] Bone Marrow Transplant. 21:1998;S30.
15. Zander A.R., Zabelina T., Kroger N., et al. Use of a five-agent GVHD prevention regimen in recipients of unrelated donor marrow. Bone Marrow Transplant. 23:1999;889-893.
16. Finke J., Bertz H., Schmoor C., et al. Allogeneic bone marrow transplantation from unrelated donors using in vivo anti-T-cell globulin. Br J Haematol. 111:2000;303-313.
17. Kroger N., Zabelina T., Kruger W., et al. In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-vs-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors. Bone Marrow Transplant. 29:2002;683-689.
18. Finke J., Schmoor C., Lang H., Potthoff K., Bertz H. Matched and mismatched allogeneic stem-cell transplantation from unrelated donors using combined graft-vs-host disease prophylaxis including rabbit anti-T lymphocyte globulin. J Clin Oncol. 21:2003;506-513.
19. Thomas E.D., Storb R., Clift R.A., et al. Bone-marrow transplantation. [second of two parts] N Engl J Med. 292:1975;895-902.
20. Meijer E., Dekker A.W., Rozenberg-Arska M., Weersink A.J.L., Verdonck L.F. Influence of cytomegalovirus-seropositivity on outcome after T cell depleted bone marrow transplantation: contrasting results between recipients of grafts from related and unrelated donors. Clin Infect Dis. 35:2002;703-712.
21. Meijer E., Dekker A.W., Verdonck L.F. Influence of antithymocyteglobulin dose on outcome in cytomegalovirus-seropositive recipients of partially T cell depleted stem cell grafts from matched unrelated donors. Br J Haematol. 121:2003;473-476.